Document Detail


Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus.
MedLine Citation:
PMID:  8996228     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Platelet hyperactivity has been one of the mechanisms implicated in the pathogenesis of diabetic retinopathy. Antiplatelet agents have been shown, in experimental models, to prevent the development of retinal vascular abnormalities when given from the first day after the onset of diabetes. We assessed the effect of aspirin plus dipyridamole (6 + 12 mg/kg daily) on the retinal vascular pattern in experimental streptozotocin-induced diabetes in rats, when the treatment was given at different intervals after the induction of diabetes, over a 3-month study period. Saline-pretreated diabetic rats showed a time-dependent increases in the platelet production of thromboxane B2 (r = 0.981, P < .0001) and a decrease in the aortic production of 6-keto-PGF1 alpha. The percentage of retinal area occupied by horseradish peroxidase-labeled vessels decreased progressively in relation to the length of time of the evolution of diabetes (r = 0.983, P < .00001) and the thromboxane/prostacyclin ratio. Treatment with aspirin plus dipyridamole caused an inhibition of the platelet production of thromboxane B2 and a decrease in the vascular synthesis of prostacyclin. Treatment with antiplatelet agents slowed down the decrease in the percentage of retinal area occupied by horseradish peroxidase-labeled vessels. These data provide further evidence to support the results of previous clinical trials in which antiplatelet agents had a beneficial effect on the evolution of retinal lesions in early diabetic retinopathy.
Authors:
J P De la Cruz; A Moreno; M Muñoz; J M García Campos; F Sánchez de la Cuesta
Related Documents :
24143048 - Mitigation of starch and glucose-induced postprandial glycemic excursion in rats by ant...
25287058 - Rnase l contributes to experimentally induced type i diabetes onset in mice.
20484588 - Multifocal erg defects associated with insufficient long-term glycemic control in adole...
23204848 - Frequency of diabetes, impaired fasting glucose, and glucose intolerance in high-risk g...
24436478 - Clinical correlates of insulin sensitivity and its association with mortality among men...
18477508 - Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent an...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  280     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  1997 Jan 
Date Detail:
Created Date:  1997-02-10     Completed Date:  1997-02-10     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  454-9     Citation Subset:  IM    
Affiliation:
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Ketoprostaglandin F1 alpha / biosynthesis
Animals
Aspirin / pharmacology*
Diabetes Mellitus, Experimental / drug therapy*,  pathology
Dipyridamole / pharmacology*
Epoprostenol / biosynthesis
Male
Platelet Aggregation Inhibitors / pharmacology*
Rats
Rats, Sprague-Dawley
Retina / drug effects*,  pathology
Streptozocin
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 18883-66-4/Streptozocin; 35121-78-9/Epoprostenol; 50-78-2/Aspirin; 58-32-2/Dipyridamole; 58962-34-8/6-Ketoprostaglandin F1 alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  HR 720, a novel angiotensin receptor antagonist inhibits the angiotensin II-induced trophic effects,...
Next Document:  Mechanisms of the regional hemodynamic effects of a mu-opioid receptor agonist microinjected into th...